Article ; Online: Outcome of sirolimus-based immunosuppression, fifteen years post-live-donor kidney transplantation: Single-center experience.
2019 Volume 33, Issue 2, Page(s) e13463
Abstract: In a prospective randomized controlled trial, between May 2001 and January 2003, 132 live-donor kidney transplant recipients were randomized to receive sirolimus primary immunosuppression, either in combination with low dose tacrolimus (Tac group) or in ... ...
| Abstract | In a prospective randomized controlled trial, between May 2001 and January 2003, 132 live-donor kidney transplant recipients were randomized to receive sirolimus primary immunosuppression, either in combination with low dose tacrolimus (Tac group) or in combination with mycophenolate mofetil (MMF group). We have previously reported on 2- and 5-year follow-up results, with favorable patient and graft outcomes obtained in both groups. In view of recent published reports of increased risk of inferior outcomes among sirolimus-treated patients, we herein present results of an observational extension of the previously randomized patients 15 years post-transplantation. Mortality rates were 10.8% and 3% in Tac and MMF groups respectively after mean follow-up period of 11.2-11.8 years. Comparable graft survival rates were obtained in both groups ranging from 60% to 62.7%. The (MMF) group continued to have the advantage of remaining on primary plan of immunosuppression (56.7% of patients) as well as to maintain better graft function in terms of serum creatinine level. Herein, we presented longest term published data for sirolimus-based immunosuppression among live-donor kidney transplants with favorable outcome in terms of survival and graft function. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adolescent ; Female ; Follow-Up Studies ; Glomerular Filtration Rate ; Graft Rejection/drug therapy ; Graft Rejection/etiology ; Graft Rejection/mortality ; Graft Survival/drug effects ; Humans ; Immunosuppressive Agents/administration & dosage ; Kidney Failure, Chronic/surgery ; Kidney Function Tests ; Kidney Transplantation/adverse effects ; Kidney Transplantation/mortality ; Male ; Mycophenolic Acid/administration & dosage ; Prognosis ; Retrospective Studies ; Risk Factors ; Sirolimus/administration & dosage ; Survival Rate ; Tissue Donors/supply & distribution | |||||
| Chemical Substances | Immunosuppressive Agents ; Mycophenolic Acid (HU9DX48N0T) ; Sirolimus (W36ZG6FT64) | |||||
| Language | English | |||||
| Publishing date | 2019-01-20 | |||||
| Publishing country | Denmark | |||||
| Document type | Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't | |||||
| ZDB-ID | 639001-8 | |||||
| ISSN | 1399-0012 ; 0902-0063 | |||||
| ISSN (online) | 1399-0012 | |||||
| ISSN | 0902-0063 | |||||
| DOI | 10.1111/ctr.13463 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2204: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.